Quinolones show excellent antibacterial activity against Salmonella isolates. Recently, however, quinolone resistance has been increasing in bacteria. This study aimed to examine in vitro, and compare the activity of DC-159a against Salmonella enterica serovar Typhimurium with that of ciprofloxacin and nalidixic acid. Inhibitory effects of quinolones were assessed by the drug concentration needed to inhibit the supercoiling activity of recombinant DNA gyrases by 50% (IC50). Dilution methods were used to determine the minimum inhibitory concentration (MIC) of quinolones against two different strains, Salmonella Typhimurium and Salmonella Enteritidis. The IC50s of DC-159a against mutant DNA gyrases were much lower than those of nalidixic acid and ciprofloxacin. In particular, the IC50 of DC-159a against DNA gyrase with double mutation was less than 1/50 that of ciprofloxacin and nalidixic acid. MICs of DC-159a were higher than those of ciprofloxacin but lower than those of nalidixic acid. However, the estimated MICs of DC-159a against Salmonella strains with mutant DNA gyrase were lower than those of ciprofloxacin and nalidixic acid. Therefore, DC-159a can be suggested as an antibiotic candidate for treating salmonellosis caused by quinolone-resistant S. Typhimurium.
Get full access to this article
View all access options for this article.
References
1.
WongM.H.Y., YanM., ChanE.W.C., BiaoK., and ChenS.. 2014. Emergence of clinical Salmonella enterica serovar Typhimurium isolates with concurrent resistance to ciprofloxacin, ceftriaxone, and azithromycin. Antimicrob. Agents Chemother., 58:3752–3756.
2.
MajowiczS.E., MustoJ., ScallanE., AnguloF.J., KirkM., O'BrienS.J., JonesT.F., FazilA., and HoekstraR.M.. 2010. The global burden of nontyphoidal Salmonella gastroenteritis. Clin. Infect. Dis., 50:882–889.
3.
HelmsM., VastrupP., Gerner-SmidtP., and MølbakK.. 2002. Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium. Emerg. Infect. Dis., 8:490–495.
4.
HendriksenR.S., VieiraA.R., KarlsmoseS., Lo Fo WongD.M.A., JensenA.B., WegenerH.C., and AarestrupF.M.. 2011. Global monitoring of Salmonella serovar distribution from the World Health Organization Global Foodborne Infections Network Country Data Bank: results of quality assured laboratories from 2001 to 2007. Foodborne Pathog. Dis., 8:887–900.
DrlicaK., and ZhaoX.. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev., 61:377–392.
10.
ReeceR.J., and MaxwellA.. 1991. DNA gyrase: structure and function. Crit. Rev. Biochem. Mol. Biol., 26:335–375.
11.
ChampouxJ.J.2001. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem., 70:369–413.
12.
SmithJ.T.1986. Mechanism of action of quinolones. Infection, 14Suppl 1:S3–S15.
13.
CloeckaertA., and Chaslus-DanclaE.. 2001. Mechanisms of quinolone resistance in Salmonella. Vet. Res., 32:291–300.
14.
FàbregaA., MadurgaS., GiraltE., and VilaJ.. 2009. Mechanism of action of and resistance to quinolones. Microb. Biotechnol., 2:40–61.
15.
RuizJ.2003. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother., 51:1109–1117.
16.
JacobyG.A.2005. Mechanisms of resistance to quinolones. Clin. Infect. Dis., 41Suppl 2:S120–S126.
17.
de SouzaR.B., MagnaniM., FerrariR.G., KottwitzL.B.M., SartoriD., TognimM.C.B., and de OliveiraT.C.R.M.2011. Detection of quinolone-resistance mutations in salmonella spp. Strains of epidemic and poultry origin. Braz. J. Microbiol., 42:211–215.
18.
AldredK.J., McPhersonS.A., TurnboughC.L., KernsR.J., and OsheroffN.. 2013. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res., 41:4628–4639.
19.
PalùG., ValisenaS., CiarrocchiG., GattoB., and PalumboM.. 1992. Quinolone binding to DNA is mediated by magnesium ions. Proc. Natl. Acad. Sci. U S A, 89:9671–9675.
20.
PiddockL.2002. Fluoroquinolone resistance in Salmonella serovars isolated from humans and food animals. FEMS Microbiol. Rev., 26:3–16.
21.
LingJ.M., ChanE.W., LamA.W., and ChengA.F.. 2003. Mutations in topoisomerase genes of fluoroquinolone-resistant Salmonellae in Hong Kong. Antimicrob. Agents Chemother., 47:3567–3573.
22.
CasinI., BreuilJ., DarchisJ.P., GuelpaC., and CollatzE.. 2003. Fluoroquinolone resistance linked to GyrA, GyrB, and ParC mutations in Salmonella enterica Typhimurium isolates in humans. Emerg. Infect. Dis., 9:1455–1457.
23.
VilaJ., RuizJ., MarcoF., BarceloA., GoniP., GiraltE., and De AntaT.J.. 1994. Association between double mutation in gyrA gene of ciprofloxacin- resistant clinical isolates of Escherichia coli and MICs. Antimicrob. Agents Chemother., 38:2477–2479.
24.
CrumplinG.C., and SmithJ.T.. 1975. Nalidixic acid: an antibacterial paradox. Antimicrob. Agents Chemother., 8:251–261.
25.
SharmaP.C., JainA., and JainS.. 2009. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol. Pharm., 66:587–604.
26.
TakahashiH., HayakawaI., and AkimotoT.. 2003. The history of the development and changes of quinolone antibacterial agents. Yakushigaku Zasshi., 38:161–179.
27.
TillotsonG.S.1996. Quinolones: structure-activity relationships and future predictions. J. Med. Microbiol., 44:320–324.
28.
BallA.P.1986. Overview of clinical experience with ciprofloxacin. Eur. J. Clin. Microbiol., 5:214–219.
29.
World Health Organizatio. 2015. 19th WHO Model List of Essential Medicines. WHO Press, World Health Organization, Geneva.
30.
HsuehP.-R., TengL.-J., TsengS.-P., ChangC.-F., WanJ.-H., YanJ.-J., LeeC.-M., ChuangY.-C., HuangW.-K., YangD., ShyrJ.-M., YuK.-W., WangL.-S., LuJ.-J., KoW.-C., WuJ.-J., ChangF.-Y., … and LuhK.-T.. 2004. Ciprofloxacin-resistant Salmonella enterica Typhimurium and choleraesuis from pigs to humans, Taiwan. Emerg. Infect. Dis., 10:60–68.
31.
Al-MashhadaniM., HewsonR., VivancosR., KeenanA., BeechingN.J., WainJ., and ParryC.M.. 2011. Foreign travel and decreased ciprofloxacin susceptibility in Salmonella enterica infections. Emerg. Infect. Dis., 17:123–125.
32.
YamaguchiT., YokoyamaK., NakajimaC., and SuzukiY.. 2016. DC-159a shows inhibitory activity against DNA gyrases of mycobacterium leprae. PLoS Negl. Trop. Dis., 10:e0005013.
33.
DisratthakitA., and DoiN.. 2010. In vitro activities of DC-159a, a novel fluoroquinolone, against mycobacterium species. Antimicrob. Agents Chemother., 54:2684–2686.
34.
ClarkC., SmithK., EdnieL., BogdanovichT., DewasseB., McGheeP., and AppelbaumP.C.. 2008. In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother., 52:77–84.
35.
HoshinoK., InoueK., MurakamiY., KurosakaY., NambaK., KashimotoY., UoyamaS., OkumuraR., HiguchiS., and OtaniT.. 2008. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob. Agents Chemother., 52:65–76.
36.
KongsoiS., ChangkwanyeunR., YokoyamaK., NakajimaC., ChangkaewK., SuthienkulO., and SuzukiY.. 2016. Amino acid substitutions in GyrA affect quinolone susceptibility in Salmonella typhimurium. Drug Test. Anal., 8:1065–1070.
37.
Clinical and Laboratory Standards Institute.. 2017. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.
38.
KongsoiS., YokoyamaK., SuprasertA., UtrarachkijF., NakajimaC., SuthienkulO., and SuzukiY.. 2015. Characterization of Salmonella Typhimurium DNA gyrase as a target of quinolones. Drug Test. Anal., 7:714–720.
39.
FisherL.M., and PanX.-S.. 2008. Methods to assay inhibitors of DNA gyrase and topoisomerase IV Activities. Methods Mol. Med., 142:11–23.
40.
SebaughJ.L.2011. Guidelines for accurate EC50/IC50 estimation. Pharm. Stat., 10:128–134.
41.
Clinical and Laboratory Standards Institute.. 2012. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. Clinical and Laboratory Standards Institute, Wayne, PA.
42.
GriggsD.J., GensbergK., and PiddockL.J.. 1996. Role of mutation in the gyrA and parC genes of nalidixic-acid-resistant salmonella serotypes isolated from animals in the United Kingdom. Antimicrob. Agents Chemother., 40:1009–1013.
43.
GriggsD.J., GensbergK., and PiddockL.J.. 1996. Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from humans and animals. These include: Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from humans and animals. Antimicrob. Agents Chemother., 40:1009–1013.
44.
PetersonL.R.2001. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin. Infect. Dis., 33Suppl 3:S180–S186.
45.
ArakiT., KawaiY., OhtaI., and KitaokaH.. 2002. Photochemical behavior of sitafloxacin, fluoroquinolone antibiotic, in an aqueous solution. Chem. Pharm. Bull. (Tokyo)., 50:229–234.
46.
CuiS., LiJ., SunZ., HuC., JinS., LiF., GuoY., RanL., and MaY.. 2009. Characterization of Salmonella enterica isolates from infants and toddlers in Wuhan, China. J. Antimicrob. Chemother., 63:87–94.
47.
OteoJ., AracilB., AlósJ.I., and Gómez-GarcésJ.L.. 2000. High rate of resistance to nalidixic acid in Salmonella enterica: its role as a marker of resistance to fluoroquinolones. Clin. Microbiol. Infect., 6:273–276.
48.
GuilleminI., SougakoffW., CambauE., Revel-ViravauV., MoreauN., and JarlierV.. 1999. Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum. Microbiology, 145:2527–2532.
49.
MorrisseyI.1997. Bactericidal index: a new way to assess quinolone bactericidal activity in vitro. J. Antimicrob. Chemother., 39:713–717.
50.
GotoK., YabeK., SuzukiT., JindoT., and SanbuisshoA.. 2010. Chondrotoxicity and toxicokinetics of novel quinolone antibacterial agents DC-159a and DX-619 in juvenile rats. Toxicology, 276:122–127.
51.
AhmadZ., MinkowskiA., PeloquinC.A., WilliamsK.N., MdluliK.E., GrossetJ.H., and NuermbergerE.L.. 2011. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrob. Agents Chemother., 55:1781–1783.
52.
SteinG.E., LeBelM., FlorS.C., and ZinnyM.. 1991. Bioavailability and pharmacokinetics of oral ofloxacin formulations in normal subjects. Curr. Med. Res. Opin., 12:479–484.
53.
KingD.E., MaloneR., and LilleyS.H.. 2000. New classification and update on the quinolone antibiotics. Am. Fam. Physician, 61:2741–2748.
54.
ArakawaH., ShirasakaY., HagaM., NakanishiT., and TamaiI.. 2012. Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5. Biopharm. Drug Dispos., 33:332–341.
55.
NicolauD.P.2003. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J. Infect. Chemother., 9:292–296.
56.
OwensR.C., and AmbroseP.G.. 2005. Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis., 41Suppl 2:S144–S157.
57.
MarutaniK., MatsumotoM., OtabeY., NagamutaM., TanakaK., MiyoshiA., HasegawaT., NaganoH., MatsubaraS., KamideR., YokotaT., MatsumotoF., and UedaY.. 1993. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimicrob. Agents Chemother., 37:2217–2223.
58.
RenauT.E., GageJ.W., DeverJ.A., RolandG.E., JoannidesE.T., ShapiroM.A., SanchezJ.P., GracheckS.J., DomagalaJ.M., JacobsM.R., and ReynoldsR.C.. 1996. Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. Antimicrob. Agents Chemother., 40:2363–2368.
59.
LipskyB.A., and BakerC.A.. 1999. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis., 28:352–364.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
